Callan Family Office LLC Buys 16,443 Shares of DexCom, Inc. $DXCM

Key Points

• Callan Family Office LLC increased its stake in DexCom, Inc. by 222.5%, acquiring an additional 16,443 shares during the 2nd quarter, bringing its total holdings to 23,832 shares valued at approximately $2.08 million.
• Several analysts have given DexCom a consensus rating of "Moderate Buy" with an average price target of $97.42, amidst varying price targets from different research firms.
• DexCom's shares recently opened at $65.12, reflecting a 4.3% decrease, while the company reported $1.16 billion in revenue and $0.48 earnings per share for the last quarter.

Callan Family Office LLC lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 222.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 23,832 shares of the medical device company's stock after purchasing an additional 16,443 shares during the quarter. Callan Family Office LLC's holdings in DexCom were worth $2,080,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the business. SWS Partners acquired a new position in shares of DexCom in the 2nd quarter worth approximately $1,661,000. Baader Bank Aktiengesellschaft acquired a new position in DexCom during the second quarter worth $393,000. Assenagon Asset Management S.A. raised its holdings in DexCom by 85.7% during the second quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company's stock worth $105,469,000 after buying an additional 557,576 shares during the last quarter. Mn Services Vermogensbeheer B.V. grew its stake in shares of DexCom by 4.9% in the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company's stock worth $12,797,000 after acquiring an additional 6,800 shares in the last quarter. Finally, Shell Asset Management Co. grew its stake in shares of DexCom by 16.8% in the 2nd quarter. Shell Asset Management Co. now owns 35,812 shares of the medical device company's stock worth $3,126,000 after acquiring an additional 5,138 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on DXCM shares. Truist Financial started coverage on shares of DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 price target for the company. Canaccord Genuity Group reaffirmed a "buy" rating and set a $106.00 price objective on shares of DexCom in a report on Monday, September 29th. Argus started coverage on shares of DexCom in a report on Thursday, August 21st. They issued a "buy" rating and a $100.00 price target on the stock. Barclays raised their target price on shares of DexCom from $93.00 to $98.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 30th. Finally, Robert W. Baird lowered their target price on shares of DexCom from $112.00 to $90.00 and set an "outperform" rating on the stock in a research note on Friday, September 26th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, DexCom presently has a consensus rating of "Moderate Buy" and an average price target of $97.42.

Insider Activity at DexCom

In related news, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction on Friday, August 15th. The shares were sold at an average price of $81.06, for a total value of $222,915.00. Following the sale, the director owned 51,121 shares in the company, valued at $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Kyle Malady sold 667 shares of the business's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $80.86, for a total transaction of $53,933.62. Following the sale, the director owned 22,667 shares in the company, valued at approximately $1,832,853.62. This trade represents a 2.86% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 6,849 shares of company stock worth $564,733. 0.32% of the stock is currently owned by insiders.

DexCom Stock Down 4.3%

Shares of NASDAQ DXCM opened at $65.12 on Friday. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $93.25. The firm's fifty day moving average is $74.42 and its 200 day moving average is $77.66. The company has a market cap of $25.54 billion, a price-to-earnings ratio of 45.22, a PEG ratio of 1.37 and a beta of 1.47.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm's revenue for the quarter was up 15.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. On average, equities research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.